Contact lens discomfort—the number one reason for patient dropout—is exacerbated by heavy digital device use, which reduces blink rates and contributes to dry eye symptoms. A new addition to the Acuvue product line called Oasys Max 1-Day was designed to help, says Johnson & Johnson Vision. The company announced the product’s FDA approval today and said the lens will be available this fall.

Like the existing Oasys 1-Day, the new “Max” version is a 38% water content silicone hydrogel (senofilcon A) lens with polyvinylpyrrolidone as a wetting agent. The company says the Oasys Max also uses new, as-yet-unspecified technologies that work to optimize comfort even for lens wearers who use digital devices for extended periods each day. J&J says that overall screen time has increased by 40% in recent years, causing patients to blink up to 60% less, and that 71% of eye care professionals reported seeing patients who are experiencing eye discomfort as a result.

The following power ranges and base curves will be available for Oasys Max 1-Day: 

• Single vision: -12.00D to +8.00D in 0.25D steps (0.50D steps above ±6.00D), base curves: 8.5mm and 9.0mm.
• Multifocal: -9.00D to +6.00D (0.25D steps) with adds of low (+0.75D to +1.25D), mid (+1.50D to +1.75D) and high (+2.00D to +2.50D); base curve 8.4mm.

For more information, visit www.acuvue.com.